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OBJECTIVES: Fibromyalgia syndrome (FM) is an under diag-
nosed disorder of unknown etiology estimated between 0.5%
and 5% in the general population. There is relatively little recent
data on the epidemiology of FM world-wide, and speciﬁcally in
Europe. The aim was to estimate the prevalence of Fibromyalgia
Syndrome (FM) in clinical setting and in general population,
in ﬁve European countries with the same methodology,
METHODS: All patients addressed to the eight participating
outpatient rheumatology clinics in a month were interviewed
using the London Fibromyalgia Epidemiological Study Screening
Questionnaire adding two questions on fatigue. The diagnosis of
FM was conﬁrmed using American College of Rheumatology
classiﬁcation criteria. The questionnaire was also administered
by phone to a representative community sample more than 15
years old, selected by the quota method, in each country. The
prevalence of FM was estimated in the general population, apply-
ing the predictive positive value in consultation, to the positive
screens, RESULTS: A total of 46% of patients seen in rheuma-
tology outpatients clinics were found positive for chronic wide-
spread pain, 31.9% for widespread pain and fatigue. A total of
6.2% [15.9–16.4] were conﬁrmed to be FM. In the general
population, 13.3% were found positive for widespread pain and
6.7 % for widespread pain and fatigue. The FM prevalence in the
general population, was 4.7% [4.0–5.3], when patients screened
positive for chronic widespread pain were considered. If fatigue
is added, the prevalence was 2.9% [2.4–3.4]. FM patients had a
mean age of 54 years old (SD:12.5) and 94.1% of them where
females. These last have a greater risk (5.2 [2.6–10.3]) of having
FM. Likewise prevalence rises with age until 75–84 years, CON-
CLUSIONS: The FM prevalence, similar to that observed in
Canada and United States, represents 6 million sufferers in the
ﬁve European countries studied.
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OBJECTIVES: Fibromyalgia’s complex symptomatology means
that several instruments and questionnaires for assessing Quality
of Life are used to collect a wide variety of information. Six
questionnaires (Multidimensional Fatigue Inventory MFI, Mul-
tiple Ability Self-reportQuestionnaireMASQ, State-Trait Anxiety
Inventory STAI, Fibromyalgia Impact Questionnaire FIQ, Beck
Depression Inventory-II BDI-II, and Patient Global Impression of
Change PGIC) were validated into twelve European languages in
order to use them in international studies. METHODS: The
process, carried out in collaboration with the questionnaire
authors, comprised a forward translation by two translators who
were native speakers of the target language, a backward transla-
tion by a translator who was a native speaker of the questionnaire
source language, a review of the version obtained by an expert
clinician and a comprehension test involving ﬁve healthy subjects
from the country. RESULTS: The MFI, MASQ and STAI were
validated in the target languages. The FIQ, BDI and PGIC in the
eight, four and one missing languages. Irrespective of the ques-
tionnaire and dimensions studied, the same issues were encoun-
tered in their validation. 1) Issues were encountered in translation
in a narrow sense. For example, the word “rug” was translated as
“carpet”; 2) Literal translation was possible but largely culturally
irrelevant. For example, the expression “to walk several blocks”
was translated as “to walk more than one kilometer”; 3) Tenses
needed to be reformulated or changed for idiomatic reasons. For
example, the present perfect does not exist in German, and so the
present simple was used in the ﬁrst version. The imperfect was
eventually used with adverbs such as “lately”. CONCLUSIONS:
Linguistic validation carried out using a rigorous and recognized
method ensures that the concepts assessed are equivalent in twelve
languages and allows their use in large scale studies measuring
quality of life in ﬁbromyalgia patients.
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OBJECTIVES: The aim of this research was to estimate health-
state utilities for ﬁbromyalgia in the general population in the
United Kingdom (UK). METHODS: We used time-tradeoff
(TTO) methods to estimate utilities among the general UK popu-
lation for six Fibromyalgia health states—mild, moderate, and
severe, with and without mood symptoms. Health-state descrip-
tions included in the TTO tasks were developed using the Fibro-
myalgia Impact Questionnaire (FIQ) and input from clinical
experts. Health-states were deﬁned to map health-state utilities
into ranges of the Brief Pain Inventory (BPI)—mild = BPI 1–3;
moderate = BPI 4–6; severe = BPI 7–9. In addition to the TTO
study, utilities for comparable health states were estimated using
responses to the EQ-5D and UK tariffs, stratiﬁed by BPI score,
from among a sample of patients enrolled in a Phase III clinical
trial of duloxetine for the treatment of Fibromyalgia. RESULTS:
Sixty subjects (35 women and 25 men) from the UK general
population completed the TTO survey. The mean age was 42
(SD = 16). Each subject evaluated 3 health states. Thus, we had
30 evaluations of each of the six health states. Mean (SD) utilities
for mild, moderate, and severe Fibromyalgia without mood
symptoms were 0.86 (0.13), 0.78 (0.18), 0.53 (0.26), respec-
tively. Mean (SD) utilities for mild, moderate, and severe Fibro-
myalgia with mood symptoms were 0.82 (0.16), 0.68 (0.24),
0.45 (0.30), respectively. The ordering of utilities derived from
the EQ5-D was comparable, but EQ-5D utilities were consis-
tently lower than TTO utilities. CONCLUSIONS: cFibromyalgia
has signiﬁcant impact on patient quality-of-life. Increasing sever-
ity of symptoms is associated with lower health-state utility.
Mood symptoms cause further declines in quality-of-life. Esti-
mates using patient responses to the EQ-5D and UK general-
population tariffs are consistently lower than estimates from the
general population estimated using the TTO method.
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